Xencor increases shares offered and cuts IPO price to $7, deal size is still $75 million

By
A A A

Xencor, a biotech developing antibodies for severe autoimmune/allergic diseases and cancer, lowered the proposed deal size for its upcoming IPO on Thursday. The Monrovia, CA-based company now plans to raise $75 million by offering 10.7 million shares at $7 per share. The company had previously filed to offer 5.0 million shares at a range of $14 to $16.

Xencor, which was founded in 1997 and booked $11 million in grant and collaboration revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol XNCR. Xencor initially filed confidentially on September 11, 2013. Credit Suisse and Leerink Swann are the joint bookrunners on the deal. It is expected to price during the week of November 11, 2013.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: XNCR

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stuck
Stuck                               
Yoga Surfer
Yoga Surfer                         

Stocks

Referenced

Most Active by Volume

89,851,277
  • $17.05 ▲ 0.12%
61,694,953
  • $39.05 ▲ 1.03%
61,622,467
  • $102.64 ▲ 1.56%
56,476,509
  • $3.48 ▼ 1.14%
49,282,352
  • $5.31 ▲ 3.91%
37,301,083
  • $87.17 ▼ 3.03%
36,192,897
  • $78.29 ▲ 1.94%
33,401,171
  • $38.83 ▼ 1.89%
As of 9/23/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com